– Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares – – Fastest Developing, Most Dynamic Pharmaceutical Company in Global Healthcare – – Leading Blockbuster Franchises in Ophthalmology, Neurosciences/CNS, Medical Aesthetics/Dermatology/Plastic Medical procedures, Women's Wellness, Gastroenterology and Urology – – Positioned for Long-Term Double-Digit Organic Revenue and Earnings Development – – Double-Digit Accretion to Non-GAAP EPS within Initial 12 A few months – – Expands International Presence with Greater Marketplace and Item Reach – – Projected Synergies of in Least $1.8 Billion while Maintaining R&D Commitment of around $1 .7 Billion – – Free CASHFLOW Generation greater than $8 Billion anticipated in 2016 – – Investment Grade Rating Likely to be Maintained; Rapid Deleveraging to Below 3.5x Debt to Modified EBITDA within 12 Months – – Closing Anticipated in Q2 2015 – DUBLINandIRVINE, Calif.,Nov.

Action: Ask HHS to get rid of US water fluoridation program In January 2011, the united states Department of Health insurance and Human Services recommended reducing the degrees of fluoride added to drinking water based on national survey data showing that 41 % of American adolescents will have dental fluorosis . HHS offers proposed reducing the level of fluoride put into water from 0.7 to 1 1.2 parts per million to 0.7 ppm, by February 14 and is currently soliciting public comment due. While HHS’s decision is usually a baby step in the right path, it isn’t good enough. At the brand new recommended level Even, millions of infants will still be frequently over-exposed to fluoride, millions of American children shall continue to develop dental fluorosis, and millions of Americans – kids and adults alike – will remain at risk to the health effects caused by fluoride.